You are here

Our science / Clinical Trials / Find a Trial / NCT00878943

Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study

Back to Search Print Save as PDF Bookmark Trial

NCT00878943

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
The Institute of Medical Sciences, CARE Hospital
Hyderabad, Andra Pradesh, 500 001 India
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject who complete the A1481244 study and require Sildenafil (Revatio TM) 20 mg TID
therapy.

- All women of childbearing potential must use adequate contraception throughout the
study and four weeks after completion of the study

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant or lactating women

- Participation in other studies during study participation

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation

NCT00878943
Pfizer
No longer available
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Similar Trials

Pulmonary Arterial Hypertension
Effects of Oral Sildenafil on Mortality in Adults With PAH
NCT02060487
All Genders
18+
Years
Multiple Sites
Hypertension
Amlodipine Diabetic Hypertension Efficacy Response Trial
NCT00159692
All Genders
Pulmonary Arterial Hypertension
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
NCT01365585
All Genders
18+
Years
Multiple Sites
Obesity, Smoking, Dyslipidemia, Diabetes Mellitus, Hypertension
Africa and Middle East Cardiovascular Epidemiological Study
NCT01243138
All Genders
18+
Years
Multiple Sites
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo. This protocol provides mechanism for patients who have clinical deterioration on other PAH approved therapies to have access to sildenafil prior to marketing authorization in India.
Not Provided
Expanded Access
Drug: Sildenafil citrate
20 mg tablet to be taken thrice daily for 1 year
Not Provided
 
Temporarily not available
Contact information is only displayed when the study is recruiting subjects
India
 
 
NCT00878943
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2016

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now